What is a way to prevent rheumatic fever and rheumatic heart disease that you should educate patients on?

Choice A rationale

Forceful coughing increases intrathoracic pressure and vagal stimulation, activating the parasympathetic system to slow AV nodal conduction. This vagal maneuver transiently interrupts reentrant circuits responsible for paroxysmal supraventricular tachycardia (PSVT), restoring normal sinus rhythm. The maneuver is noninvasive, first-line, and physiologically effective for terminating AV nodal reentry tachycardia by enhancing acetylcholine-mediated suppression of nodal conduction velocity and refractory period shortening.

Choice B rationale

Bearing down as during a bowel movement, known as the Valsalva maneuver, similarly increases vagal tone. The increased intrathoracic pressure transiently reduces venous return, stimulating baroreceptors and causing reflex bradycardia. This vagal reflex inhibits reentrant impulses through the AV node, terminating PSVT episodes. The Valsalva maneuver is evidence-based, safe, and recommended as the initial nonpharmacologic intervention before pharmacologic or electrical therapy.

Choice C rationale

Jumping up and down once has no physiologic effect on vagal tone or AV nodal conduction. PSVT involves a reentrant circuit within or near the AV node, requiring vagal or pharmacologic interruption. Physical exertion like jumping may transiently increase sympathetic output, worsening tachycardia rather than terminating it. Therefore, this action provides no therapeutic value and is not recommended for PSVT management.

Choice D rationale

Adenosine rapidly blocks AV nodal conduction by hyperpolarizing nodal tissue through A1 receptor activation, effectively terminating AV nodal reentrant tachycardia. It is administered as a rapid intravenous bolus due to its 10-second plasma half-life. Adenosine temporarily induces asystole before sinus rhythm resumes. It is a first-line pharmacologic intervention when vagal maneuvers fail, demonstrating high efficacy in converting PSVT to normal sinus rhythm.

Choice A rationale

The American Heart Association (AHA) guidelines for STEMI management in non-PCI capable hospitals emphasize a Door-to-Needle time of 30 minutes for administering thrombolytic therapy. This tight window is crucial because the effectiveness of fibrinolytics in restoring coronary blood flow and minimizing myocardial damage decreases rapidly after symptom onset.

Choice B rationale

A 90-minute timeframe is the target for Door-to-Balloon time (or "Door-to-Sheath") for patients undergoing primary percutaneous coronary intervention (PCI), which is the preferred reperfusion strategy when available. This target does not apply to the administration of thrombolytics in a non-PCI setting.

Choice C rationale

While the overall goal is to provide reperfusion therapy within 12 hours of symptom onset, giving thrombolytics 6 hours after the patient presents to the hospital is too late for the "Door-to-Needle" metric. The benefit of thrombolysis significantly declines after the initial few hours.

Choice D rationale

Administering thrombolytic therapy 12 hours after the patient presents to the emergency department is typically outside the window for maximal benefit, although reperfusion may be considered up to 12-24 hours after symptom onset in specific cases if primary PCI is unavailable. The time-critical "Door-to-Needle" goal is much shorter. —.